Scope and Claim Map for U.S. Patent 9,820,959 (Ingenol Angelate Isoform ‘b’ Topical Formulation) and the U.S. Patent Estate Risk for Generics and Licensors
Executive summary: U.S. Patent 9,820,959 claims a narrow topical formulation defined by (i) isoform composition of ingenol angelate (≥95% or ≥99% as dependent claim varies), (ii) a specific ingenol-3-angelate (isoform ‘b’) concentration range (notably 0.001% to 0.15% w/w, with dependent narrowing to 0.01% to 0.1%), and (iii) a skin permeation rate window (claim 1: 11 ng/cm²/h to 1.92 μg/cm²/h). Additional dependent claim coverage tightens to acidification (pH 2.5 to 4.5; acid buffer types and 0.5% to 10%), specific solvents (benzyl alcohol at 0.9%), defined penetration enhancers (isopropyl alcohol at 30% w/w, among others), and defined gel/cream vehicles (hydroxyethylcellulose at 1.5% w/w; gel/cream/ointment/paint/lotion/foam; including storage at 2–8°C for ≥1 year). The estate is therefore strongest against noninfringing “formulation design-arounds” that alter isoform purity, permeation profile, pH/acid buffer system, solvent/enhancer identity and concentration, and vehicle rheology.
What does U.S. Patent 9,820,959 claim for ingenol angelate isoform ‘b’ topical formulations in the U.S.?
Featured-snippet answer: The patent is directed to a topical formulation whose active is ingenol-3-angelate (isoform ‘b’), with strict isoform purity, concentration, and skin permeation rate limits, plus optional vehicle and excipient-dependent limitations (acid buffer/pH, benzyl alcohol, isopropyl alcohol penetration enhancement, and gelling agents such as hydroxyethylcellulose).
Core claim scope (independent claim 1)
Claim 1 defines three hard technical boundaries that drive infringement analysis:
-
Active identity and isoform purity
- Formulation comprises ingenol angelate where ≥ about 95% of the ingenol angelate is ingenol-3-angelate (isoform ‘b’).
-
Concentration in the topical formulation
- Ingenol-3-angelate (isoform ‘b’) amount: 0.001% to 0.15% by weight.
-
In-use skin permeation window
- When applied at an effective amount, the rate of permeation across skin is between:
- 11 ng/cm²/h (lower bound) and
- 1.92 μg/cm²/h (upper bound).
This means infringement is not simply “contains isoform ‘b’.” It is “contains isoform ‘b’ at certain levels and yields a defined permeation rate profile in use.”
Dependent claim tightening that materially affects design-around risk
- Claim 2: permeation capped at ≤1 μg/cm²/h (sub-window inside claim 1).
- Claim 3: dose-area loading range 0.01 μg/cm² to 1 mg/cm².
- Claim 4: dose-area loading variant (appears to be a units/typo clause as written, but it is still a dependent numeric limiter tied to application amount).
- Claim 5-9 (acidifying system):
- acidifying agent required
- acidifying agent is an acid buffer
- buffer chosen from citrate/phosphate/acetate/citrate-phosphate; citrate in claim 8
- buffer concentration 0.5% to 10% w/w
- Claim 10-12 (solvent):
- solvent selected from PEG, methyl ethyl ketone, ethyl acetate, diethyl ether, benzyl alcohol
- specifically benzyl alcohol
- specifically 0.9% w/w benzyl alcohol
- Claim 13-15 (penetration enhancer):
- enhancer from isopropyl alcohol, sulphoxide, azone, pyrrolidone, alkanol
- specifically isopropyl alcohol
- specifically 30% w/w isopropyl alcohol
- Claim 16-20 (gelling agent/vehicle rheology):
- gelling agent defined as class of polymers/carbomer/carrageenan
- specifically hydroxyethylcellulose
- specifically 1.5% w/w
- or 1% to 5% w/w gelling agent (claim 20)
- Claim 21: concentration narrowed to 0.01% to 0.1%.
- Claim 22-23 (pH limits):
- Claim 24: isoform ‘b’ is the only active ingredient.
- Claim 25: dosage form types enumerated (gel/cream/ointment/paint/lotion/foam).
- Claim 26: sterilized.
- Claim 27-28: storage at 2–8°C for at least one year.
- Claim 29-30 (method of treatment / lesions):
- topical administration to lesions; condition list includes squamous cell carcinoma, basal cell carcinoma, malignant melanoma, actinic keratosis
- dependent on actinic keratosis
- Claim 31: composition upgrade: ≥99% of ingenol angelate is isoform ‘b’ (substantially narrower than claim 1’s ≥95%).
How do the permeation rate and isoform-purity limits functionally limit generic “copycat” formulations?
Featured-snippet answer: The patent is hard to design around because it ties infringement to a measured skin permeation rate and to isoform purity of the active drug substance, not just to “ingenol angelate” or “a topical ingenol product.”
Permeation rate as an infringement hinge
Claim 1 uses a rate of permeation range: 11 ng/cm²/h to 1.92 μg/cm²/h. Dependent claim 2 tightens the top end to ≤1 μg/cm²/h.
Practical consequences for the U.S. market:
- Even if a generic matches ingredient identity and nominal concentration, the vehicle, pH, solvent, penetration enhancer, and gelling agent can alter permeation kinetics.
- A generic seeking noninfringement could attempt to:
- move permeation below the lower bound or above the upper bound, or
- create a permeation profile outside the dependent sub-ranges.
However, claim 1’s relatively wide lower-to-upper band means design-arounds that adjust permeation modestly may still land inside the infringement interval. The most aggressive carve-out strategy is to target permeation outside both claim 1 and dependent claim 2 windows.
Isoform purity as a second hard hinge
Claim 1 requires ≥95% isoform ‘b within “ingenol angelate.” Claim 31 requires ≥99%.
This blocks easy substitution of crude or partially enriched ingenol angelate fractions:
- Any off-the-shelf active ingredient sold as “ingenol angelate” will need to be specified and controlled to the isoform purity standard.
- If the formulation uses a different mixture or upstream synthesis yields different isoform distribution, it may avoid the claim on the “≥95%” structural limit, assuming the claim is interpreted strictly as written.
Which additional limitations (pH, acid buffer, solvents, enhancers, gels) create the most U.S. infringement exposure?
Featured-snippet answer: The highest exposure clusters are excipient systems that are explicitly quantified: citrate buffer at 0.5% to 10% (and pH 2.5 to 4.5), benzyl alcohol at 0.9%, isopropyl alcohol at 30%, and hydroxyethylcellulose at 1.5% (with 1% to 5% possible).
Acidification pathway: claims 5-9 plus pH claims 22-23
- Acid buffer selected from citrate/phosphate/acetate/citrate-phosphate, with citrate specifically in claim 8.
- Buffer content 0.5% to 10% w/w.
- pH must be between 2.5 and 4.5.
This is a cohesive constraint set:
- Acid buffer identity and concentration tie directly to pH.
- A generic altering buffer chemistry can avoid one dimension, but if it still yields the same pH window it could still land within the overall dependent limitation set, depending on claim construction and which dependent claims are asserted.
Solvent and enhancer pathway: claims 10-15
- Solvent options include benzyl alcohol, with benzyl alcohol specified at 0.9% in claim 12.
- Penetration enhancer is selected from multiple classes but is specifically isopropyl alcohol at 30% in claim 15.
These are strong infringement anchors:
- A generic that replaces benzyl alcohol or lowers isopropyl alcohol concentration is more likely to avoid dependent claim coverage.
- But claim 1 can still be asserted if the vehicle changes do not remove the independent constraints (isoform purity, concentration, permeation window).
Vehicle rheology pathway: claims 16-20 plus dosage form claim 25
- Gelling agent class is enumerated; hydroxyethylcellulose is specifically recited at 1.5%.
- Dosage form types include gel/cream/ointment/paint/lotion/foam (broad).
- The vehicle details mainly matter for permeation measurement and for dependent claim 17-20 coverage.
What is the likely effective claim coverage by dosage form, storage, and sterilization in the U.S.?
Featured-snippet answer: Storage at 2–8°C for ≥1 year and sterilization appear as additional dependent claim limitations that can narrow practical infringement to products formulated to those stability and manufacturing conditions.
- Claim 26 (sterilized) could matter for manufacturing method and formulation design.
- Claim 27-28 (2–8°C, ≥1 year) matter for stability specs, labeling, and distribution logistics.
A generic could attempt to reduce risk by targeting:
- non-sterile process routes (if allowed by the commercial/labeling plan), or
- different stability testing and packaging that changes the “suitable for storage” condition.
These are dependent constraints, so the strongest independent risk remains claim 1’s composition and permeation limits.
What method-of-use claim coverage exists for actinic keratosis and other skin cancers?
Featured-snippet answer: Claim 29 covers topical treatment of selected conditions including actinic keratosis, and certain claims extend to broader skin cancer categories; dependent claim 30 narrows to actinic keratosis.
Claim 29 (method)
- Topically administering a therapeutically effective amount of the formulation of claim 1 to a skin lesion.
- Condition list: squamous cell carcinoma, basal cell carcinoma, malignant melanoma, actinic keratosis.
Claim 30 (dependent)
- Condition is actinic keratosis.
This structure is typical of estates that capture both formulation infringement and downstream product use. If a generic is designed to avoid formulation claim 1, method-of-use coverage also weakens unless a court finds that the alternative product still practices claim 1’s formulation parameters (including permeation rate and isoform purity).
How strong is the patent estate likely to be against generics or reformulations targeting actinic keratosis?
Featured-snippet answer: Strength is highest where a challenger cannot change (i) isoform purity, (ii) the permeation rate profile, or (iii) the excipient system that generates the measured permeation.
Infringement map: where challengers typically try to escape
Potential generic/reformulation pathways:
- Active substance route
- Use a different ingenol angelate fraction or lower isoform ‘b’ enrichment to avoid the “≥95%” requirement (and possibly “only active” in claim 24).
- Vehicle and excipient route
- Change solvent/enhancer and pH buffer to move permeation outside the claimed interval.
- Formulation process route
- Aim for non-sterile or different stability conditions to defeat sterilization/storage dependent limitations.
But because claim 1 is anchored to permeation rate and isoform purity, partial changes may not be enough if the overall formulation still yields the defined permeation window in a skin permeation test.
What patent landscape questions determine whether 9,820,959 blocks market entry in the U.S.?
Featured-snippet answer: The key practical questions are whether this patent is listed in the Orange Book for the relevant marketed product(s), whether it expires later than the applicant’s proposed launch date, and whether any prior or copending patents cover overlapping delivery systems, isoform purity process steps, or method-of-use indications.
Litigation and challenge risk scenarios for this claim type
For this kind of formulation/permeation claim, the highest-probability attack lines in Paragraph IV-type litigation tend to be:
- noninfringement (different permeation rate or excipient system),
- invalidity based on prior art formulations that achieve the same isoform and permeation performance, and
- lack of written description/enablement if permeation ranges are not supported with sufficient disclosure.
Because this analysis is constrained to the provided claim text only, it does not identify specific asserted references or competing patents.
How does claim narrowing (2, 21, 22-23, 31) alter the infringement surface for a generic?
Featured-snippet answer: Dependent claims are best viewed as concentric rings around claim 1. A product can avoid a dependent claim while still infringing claim 1.
Concentric ring effect (numeric tightening)
- Permeation: claim 1 up to 1.92 μg/cm²/h, claim 2 up to 1 μg/cm²/h.
- Isoform purity: claim 1 at ≥95%, claim 31 at ≥99%.
- Concentration: claim 1 at 0.001% to 0.15%, claim 21 at 0.01% to 0.1%.
- pH: claim 22/23 establish a full pH corridor 2.5 to 4.5.
In practice:
- A generic near the boundaries could still meet claim 1 while missing claim 2, 21, or 31.
- The formulation’s measured permeation and formulation pH will be determinative for whether dependent claims can be asserted.
Key takeaways
- U.S. Patent 9,820,959 is built around isoform composition (≥95% and ≥99% variants), concentration, and a quantified skin permeation rate.
- The permeation rate requirement is a primary noninfringement target because it depends on vehicle, pH, solvents, and enhancers, not just active identity.
- Dependent claim coverage is especially strong where excipients are explicitly specified and quantified: citrate buffer (0.5% to 10%), pH 2.5 to 4.5, benzyl alcohol 0.9%, isopropyl alcohol 30%, hydroxyethylcellulose 1.5%.
- Method-of-use claim coverage extends to topical treatment of skin lesions including actinic keratosis and certain skin cancers, but it tracks the infringement of claim 1’s formulation parameters.
FAQs
-
Does U.S. Patent 9,820,959 require ingenol angelate itself to be the only active ingredient?
Claim 24 states that ingenol-3-angelate (isoform ‘b’) is the only active ingredient.
-
What specific concentration range of ingenol-3-angelate (isoform ‘b’) is covered by the independent claim?
0.001% to 0.15% by weight.
-
What skin permeation range triggers infringement under claim 1?
Between 11 ng/cm²/h and 1.92 μg/cm²/h for ingenol-3-angelate (isoform ‘b’).
-
Can a product avoid infringement by using a different acid buffer?
It may avoid dependent claim 7-9 coverage, but it must still avoid independent claim 1 by ensuring it does not meet the claim 1 isoform purity, concentration, and permeation limits.
-
Is actinic keratosis explicitly covered by a method-of-use claim?
Yes. Claim 30 narrows claim 29 to actinic keratosis.
References (APA)
No sources were provided or cited in the prompt text.
